MAPT and Alzheimer disease: Yet, over the last 20 years, many of the potential drugs that target tau and Aβ, the two hallmarks of AD, failed in clinical trials, though some of treatments were effective in AD animal models (Zahs and Ashe, 2010; Shineman et al., 2011; Hall and Roberson, 2012).